This Article Full Text Full Text (PDF) All Versions of this Article: 105/12/1440    most recent 01.CIR.0000012145.80593.25v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Flavell, D. M. Articles by Syvänne, M. Search for Related Content PubMed PubMed Citation Articles by Flavell, D. M. Articles by Syvänne, M. Related Collections Genetics of cardiovascular disease Lipid and lipoprotein metabolism Energy metabolism Gene regulation

(Circulation. 2002;105:1440.)
© 2002 American Heart Association, Inc.

Peroxisome Proliferator-Activated Receptor Gene Variants Influence Progression of Coronary Atherosclerosis and Risk of Coronary Artery Disease

David M. Flavell, PhD; Yalda Jamshidi, PhD; Emma Hawe, MSc; Inés Pineda Torra, PhD; Marja-Riitta Taskinen, MD; M. Heikki Frick, MD; Markku S. Nieminen, MD; Y. Antero Kesäniemi, MD; Amos Pasternack, MD; Bart Staels, PhD; George Miller, MD; Steve E. Humphries, PhD FRCPath, MRCP; Philippa J. Talmud, PhD DSc, FRCPath; Mikko Syvänne, MD

From the Centre for Cardiovascular Genetics, Department of Medicine, Royal Free and University College of London Medical School, London, UK (D.M.F., Y.J., E.H., S.E.H., P.J.T.); U.325 INSERM, Département d’Athérosclérose, Institut Pasteur, Lille, France (I.P.T., B.S.); the Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (M.-R.T., M.H.F., M.S.N., M.S.); the Department of Medicine, University of Oulu, Oulu, Finland (Y.A.K.); the Department of Medicine, Tampere University Hospital, Tampere, Finland (A.P.); and Medical Research Council Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, The Medical College of St Bartholomew’s Hospital, London, UK (G.M.).

Correspondence to David M. Flavell, Centre for Cardiovascular Genetics, Department of Medicine, Royal Free and University College of London Medical School, Rayne Building, 5 University St, London WC1E 6JJ, UK. E-mail d.flavell{at}ucl.ac.uk

Background— Peroxisome proliferator-activated receptor (PPAR) regulates the expression of genes involved in lipid metabolism and inflammation, making it a candidate gene for atherosclerosis and ischemic heart disease (IHD).

Methods and Results— We investigated the association between the leucine 162 to valine (L162V) polymorphism and a G to C transversion in intron 7 of the PPAR gene and progression of atherosclerosis in the Lopid Coronary Angiography Trial (LOCAT), a trial examining the effect of gemfibrozil treatment on progression of atherosclerosis after bypass surgery and on risk of IHD in the second Northwick Park Heart Study (NPHS2), a prospective study of healthy middle-aged men in the United Kingdom. There was no association with plasma lipid concentrations in either study. Both polymorphisms influenced progression of atherosclerosis and risk of IHD. V162 allele carriers had less progression of diffuse atherosclerosis than did L162 allele homozygotes with a similar trend for focal atherosclerosis. Intron 7 C allele carriers had greater progression of atherosclerosis than did G allele homozygotes. The V162 allele attenuated the proatherosclerotic effect of the intron 7 C allele. Homozygotes for the intron 7 C allele had increased risk of IHD, an effect modulated by the L162V polymorphism

Conclusions— The PPAR gene affects progression of atherosclerosis and risk of IHD. Absence of association with plasma lipid concentrations suggests that PPAR affects atherosclerotic progression directly in the vessel wall.

Key Words: atherosclerosis • genetics • coronary disease

This article has been cited by other articles:

				M. H. Liu, J. Li, P. Shen, B. Husna, E. S. Tai, and E. L. Yong A Natural Polymorphism in Peroxisome Proliferator-Activated Receptor-{alpha} Hinge Region Attenuates Transcription due to Defective Release of Nuclear Receptor Corepressor from Chromatin Mol. Endocrinol., May 1, 2008; 22(5): 1078 - 1092. [Abstract] [Full Text] [PDF]

				V. R. Babaev, H. Ishiguro, L. Ding, P. G. Yancey, D. E. Dove, W. J. Kovacs, C. F. Semenkovich, S. Fazio, and M. F. Linton Macrophage Expression of Peroxisome Proliferator Activated Receptor-{alpha} Reduces Atherosclerosis in Low-Density Lipoprotein Receptor Deficient Mice Circulation, September 18, 2007; 116(12): 1404 - 1412. [Abstract] [Full Text] [PDF]

				T. Tanaka, J. M. Ordovas, J. Delgado-Lista, F. Perez-Jimenez, C. Marin, P. Perez-Martinez, P. Gomez, and J. Lopez-Miranda Peroxisome proliferator-activated receptor {alpha} polymorphisms and postprandial lipemia in healthy men J. Lipid Res., June 1, 2007; 48(6): 1402 - 1408. [Abstract] [Full Text] [PDF]

				A. J. Gilde, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32. [Abstract] [Full Text] [PDF]

				D. M. Flavell, H. Ireland, J. W. Stephens, E. Hawe, J. Acharya, H. Mather, S. J. Hurel, and S. E. Humphries Peroxisome Proliferator-Activated Receptor {alpha} Gene Variation Influences Age of Onset and Progression of Type 2 Diabetes Diabetes, February 1, 2005; 54(2): 582 - 586. [Abstract] [Full Text] [PDF]

				Q H Khan, D E Pontefract, S Iyengar, and S Ye Evidence of differing genotypic effects of PPAR{alpha} in women and men J. Med. Genet., June 1, 2004; 41(6): e79 - e79. [Full Text] [PDF]

				N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF]

				P. J. Talmud, S. Martin, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, Y. A. Kesaniemi, A. Pasternack, S. E. Humphries, and M. Syvanne APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study J. Lipid Res., April 1, 2004; 45(4): 750 - 756. [Abstract] [Full Text] [PDF]

				S. E. Humphries, P. M. Ridker, and P. J. Talmud Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation? Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 628 - 636. [Abstract] [Full Text] [PDF]

				M Vytopil, S Benedetti, E Ricci, G Galluzzi, A Dello Russo, L Merlini, G Boriani, M Gallina, L Morandi, L Politano, et al. Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes J. Med. Genet., December 1, 2003; 40(12): e132 - 132. [Full Text]

				P. J. Talmud, S. Martin, G. Steiner, D. M. Flavell, D. B. Whitehouse, S. Nagl, R. Jackson, M.-R. Taskinen, M. H. Frick, M. S. Nieminen, et al. Progression of Atherosclerosis Is Associated With Variation in the {alpha}1-Antitrypsin Gene Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 644 - 649. [Abstract] [Full Text] [PDF]